It’s a common pharma problem—win the battle but lose the war. Lots of drugs use the surrogate end point as proof it works but don’t look at all cause mortality. Cancer drugs especially.
It’s a common pharma problem—win the battle but lose the war. Lots of drugs use the surrogate end point as proof it works but don’t look at all cause mortality. Cancer drugs especially.
Surrogate end markers. The scourge of missing valid end points. There is already a push to use antibody response as the surrogate end marker for vaccine efficacy. Like that'll turn out fantastic.
I am so pleased that these brilliant people on substack are now speaking up for Mortality and Morbidity as being the correct endpoints for ANY trial...not infection.
Bravo! Please keep repeating this..because our excess mortality and mobidity stats are FRIGHTENING.
It’s a common pharma problem—win the battle but lose the war. Lots of drugs use the surrogate end point as proof it works but don’t look at all cause mortality. Cancer drugs especially.
Surrogate end markers. The scourge of missing valid end points. There is already a push to use antibody response as the surrogate end marker for vaccine efficacy. Like that'll turn out fantastic.
it is a common for profit, wag the fda pharma problem.
my experience in weapon testing: fda is worse than dod, and fda has a revolving door just as the pentagon alums....
I am so pleased that these brilliant people on substack are now speaking up for Mortality and Morbidity as being the correct endpoints for ANY trial...not infection.
Bravo! Please keep repeating this..because our excess mortality and mobidity stats are FRIGHTENING.